Cited by 353Pharmaceutical studies and practicesPharmacogenetics and Drug MetabolismAnimal testing and alternatives

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

Jones, Hannah M, Parrott, Neil, Jorga, Karin, Lav??, Thierry·2006·Clinical Pharmacokinetics

DOI 10.2165/00003088-200645050-00006

Open this paper in CoChat — free account

Abstract

Background The major aim of this study was to develop a strategy for predicting human pharmacokinetics using physiologically based pharmacokinetic (PBPK) modelling. This was compared with allometry (of plasma concentration-time profiles using the Dedrick approach), in order to determine the best approaches and strategies for the prediction of human pharmacokinetics.Methods PBPK and Dedrick predictions were made for 19 F. Hoffmann-La Roche compounds. A strategy for the prediction of human pharmacokinetics using PBPK modelling was proposed in this study. Predicted values (pharmacokinetic parameters, plasma concentrations) were compared with observed values obtained after intravenous and oral administration in order to assess the accuracy of the prediction methods.Results By following the proposed strategy for PBPK, a prediction would have been made prospectively for approximately 70% of the compounds. The prediction accuracy for these compounds in terms of the percentage of compounds with an average-fold error of <2-fold was 83%, 50%, 75%, 67%, 92% and 100% for apparent oral clearance (CL/F), apparent volume of distribution during terminal phase after oral administration (V(z)/F), terminal elimination half-life (t(1/2)), peak plasma concentration (C(max)), area under the plasma concentration-time curve (AUC) and time to reach C(max) (t(max)), respectively. For the other 30% compounds, unacceptable prediction accuracy was obtained in animals; therefore, a prospective prediction of human pharmacokinetics would not have been made using PBPK. For these compounds, prediction accuracy was also poor using the Dedrick approach. In the majority of cases, PBPK gave more accurate predictions of pharmacokinetic parameters and plasma concentration-time profiles than the Dedrick approach.Conclusions Based on the dataset evaluated in this study, PBPK gave reasonable predictions of human pharmacokinetics using preclinical data and is the recommended approach in the majority of cases. In addition, PBPK modelling is a useful tool to gain insights into the properties of a compound. Thus, PBPK can guide experimental efforts to obtain the relevant information necessary to understand the compound's properties before entry into human, ultimately resulting in a higher level of prediction accuracy.

Integrity signals

Registry

Crossref · 10.2165/00003088-200645050-00006

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Physiological Parameter Values for Physiologically Based Pharmacokinetic Models
Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., & Beliles, R. P. (1997) · Toxicology and Industrial Health · doi:10.1177/074823379701300401 · Cited by 1,408
Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes
Kansy, M., Senner, F., & Gubernator, K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970530e · Cited by 1,304
Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925
Characterization of Interintestinal and Intraintestinal Variations in Human CYP3A-Dependent Metabolism
Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 790
Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong Bases
Rodgers, T., Leahy, D., & Rowland, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20322 · Cited by 776
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Predicting the Impact of Physiological and Biochemical Processes on Oral Drug Bioavailability
Agoram, B., Woltosz, W. S., & Bolger, M. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00179-x · Cited by 651
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 4×
“[5,25,45] In contrast, allometric scaling has long been the dominant method for interspecies’ scaling;[2,3,6,7] however, owing to its empirical nature and its failure to account for differences in pharmacokinetics across 0.”
BackgroundMethodInfluential

Show all 76 references

Research works printed but not linked: 11

Bernareggi, 1991, J Pharm Sci, 19, 21
Dedrick, 1970, Cancer Chemother Rep, 54, 95
Yokogawa, 1990, Drug Metab Dispos, 18, 258
Carlile, 1997, Drug Metab Dispos, 25, 903
Naritomi, 2001, Drug Metab Dispos, 29, 1316
Lin, 1998, Drug Metab Dispos, 26, 1202
Lave, 1996, J Pharm Sci, 48, 573
Poggesi, 2004, Curr Opin Drug Discov Devel, 7, 100
Paine, 1997, J Pharmacol Exp Ther, 283, 1552
Obach, 1996, Drug Metab Dispos, 24, 1047
Obach, 1997, Drug Metab Dispos, 25, 1359

Sorted by citations

Items 101–200 of 353

Effect of Ritonavir on99mTechnetium–Mebrofenin Disposition in Humans: A Semi‐PBPK Modeling andIn VitroApproach to Predict Transporter‐Mediated DDIs
Pfeifer, N. D., Goss, S., Swift, B., Ghibellini, G., Ivanović, M., Heizer, W. D., Gangarosa, L. M., & Brouwer, K. L. R. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.21 · Cited by 45
Prediction of Vss from In Vitro Tissue-Binding Studies
Berry, L., Roberts, J. T., Be, X., Zhao, Z., & Lin, M.-H. J. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029629 · Cited by 44
Model-based drug development: application of modeling and simulation in drug development
Kim, T., Shin, S., & Shin, B. S. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0371-3 · Cited by 45
IMI – oral biopharmaceutics tools project – evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds
Margolskee, A., Darwich, A. S., Pepin, X., Pathak, S. M., Bolger, M. B., Aarons, L., Rostami-Hodjegan, A., Angstenberger, J., Graf, F., Laplanche, L., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.09.027 · Cited by 43
Utility of physiologically based pharmacokinetic modeling in predicting and characterizing clinical drug interactions
Foti, R. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001384 · Cited by 43
A Physiologically Based Pharmacokinetic Model of Rifampin in Mice
Lyons, M. A., Reisfeld, B., Yang, R. S. H., & Lenaerts, A. J. M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01567-12 · Cited by 43
A critical assessment of in vitro tissue models for ADME and drug delivery
Vellonen, K., Malinen, M. M., Mannermaa, E., Subrizi, A., Toropainen, E., Lou, Y., Kidron, H., Yliperttula, M. L., & Urtti, A. O. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.044 · Cited by 43
Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™
Sun, F., Lee, L., Zhang, Z., Wang, X., Yu, Q., Duan, X., & Chan, E. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.06.021 · Cited by 42
ECVAM and New Technologies for Toxicity Testing
d’Yvoire, M. B., Bremer, S., Casati, S., Ceridono, M., Coecke, S., Corvi, R., Eskes, C., Gribaldo, L., Griesinger, C. B., Knaut, H., et al. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3055-1_10 · Cited by 40
Multiparametric assay using HepaRG cells for predicting drug-induced liver injury
貴文, 富., Okamura, H., Satsukawa, M., Yokoi, T., & Konno, Y. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.04.014 · Cited by 38
Prediction of volume of distribution at steady state in humans: comparison of different approaches
Zou, P., Zheng, N., Yang, Y., Yu, L. X., & Sun, D. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.682569 · Cited by 39
Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products – a PEARRL review
Guimarães, M., Statelova, M., Holm, R., Reppas, C. I., Symillides, M., Vertzoni, M., & Fotaki, N. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12955 · Cited by 37
Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology
Maurer, T. S., Ghosh, A., Haddish‐Berhane, N., Sawant‐Basak, A., Boustany, C., She, L., Leininger, M. T., Zhu, T., Tugnait, M., Yang, X., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9297-2 · Cited by 37
Mass Spectrometry-Based Quantification of CYP Enzymes to Establish In Vitro/In Vivo Scaling Factors for Intestinal and Hepatic Metabolism in Beagle Dog
Heikkinen, A. T., Friedlein, A., Lamerz, J., Jakob, P., Cutler, P., Fowler, S. M., Williamson, T., Tolando, R., Lavé, T., & Parrott, N. J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0707-7 · Cited by 36
Self-citation
Importance of target-mediated drug disposition for small molecules
Smith, D. A., van Waterschoot, R. A. B., Parrott, N. J., Olivares‐Morales, A., Lavé, T., & Rowland, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.06.010 · Cited by 36
Self-citation
Prediction of Human Pharmacokinetics From Chemical Structure: Combining Mechanistic Modeling with Machine Learning
Grüber, A., Führer, F., Menz, S., Diedam, H., Göller, A. H., & Schneckener, S. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.035 · Cited by 35
Why We Need Proper PBPK Models to Examine Intestine and Liver Oral Drug Absorption
Chow, E. C. Y., & Pang, K. S. (2012) · Current Drug Metabolism · doi:10.2174/1389200211309010057 · Cited by 45
Pharmacokinetics of Paracetamol in Göttingen Minipigs: In Vivo Studies and Modeling to Elucidate Physiological Determinants of Absorption
Suenderhauf, C., Tuffin, G., Lorentsen, H., Grimm, H.-P., Flament, C., & Parrott, N. J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1367-6 · Cited by 37
Self-citation
Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data
Heimbach, T., Lakshminarayana, S. B., Hu, W., & He, H. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9136-x · Cited by 36
Projection of Exposure and Efficacious Dose Prior to First-in-Human Studies: How Successful Have We Been?
Huang, C., Zheng, M., Yang, Z., Rodrigues, A. D., & Marathe, P. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9411-4 · Cited by 35
Prediction of Pharmacokinetic Profile of Valsartan in Humans Based onin vitroUptake‐Transport Data
Poirier, A., Cascais, A., Funk, C., & Lavé, T. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900116 · Cited by 34
Self-citation
Prediction of Human Oral Plasma Concentration-Time Profiles Using Preclinical Data: Comparative Evaluation of Prediction Approaches in Early Pharmaceutical Discovery
Van den Bergh, A., Sinha, V., Gilissen, R., Straetemans, R., Wuyts, K., Morrison, D., Bijnens, L., & Mackie, C. (2011) · Clinical Pharmacokinetics · doi:10.2165/11587230-000000000-00000 · Cited by 33
Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across PermeapadⓇ membrane and in vivo absorption
Ilie, A.-R., Griffin, B. T., Brandl, M., Bauer-Brandl, A., Jacobsen, A.-C., Vertzoni, M., Kuentz, M., Kolakovic, R., & Holm, R. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105452 · Cited by 33
Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model
Li, J., Guo, H., Liu, C., Zhong, Z., Liu, L., & Liu, X. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0192-8 · Cited by 33
Physiologically based pharmacokinetic‐pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics
Martins, F. S., Zhu, P., Heinrichs, M. T., & Sy, S. K. B. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14456 · Cited by 34
Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development
Caruso, A., Frances, N., Meille, C., Greiter‐Wilke, A., Hillebrecht, A., & Lavé, T. (2014) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2014.05.004 · Cited by 32
Self-citation
Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz
Siccardi, M., Olagunju, A., Seden, K., Ebrahimjee, F., Rannard, S. P., Back, D. J., & Owen, A. (2013) · In Silico Pharmacology · doi:10.1186/2193-9616-1-4 · Cited by 32
Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model
Hardiansyah, D., Riana, A., Beer, A. J., & Glatting, G. (2022) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2022.06.004 · Cited by 32
Prediction of Drug Disposition on the Basis of its Chemical Structure
Stepensky, D. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0042-0 · Cited by 33
Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study
Germani, M., Crivori, P., Rocchetti, M., Burton, P. S., Wilson, A., Smith, M. E., & Poggesi, I. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.03.008 · Cited by 32
Tissue lipids and drug distribution: Dog versus rat
Rodgers, T., Jones, H. M., & Rowland, M. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23285 · Cited by 31
Self-citation
Quantitative Prediction of Human Clearance Guiding the Development of Raltegravir (MK-0518, Isentress) and Related HIV Integrase Inhibitors
Laufer, R., Paz, O. G., Marco, A. D., Bonelli, F., Monteagudo, E. S., Summa, V., & Rowley, M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023804 · Cited by 31
Prediction of Human Pharmacokinetics from Preclinical Information of Rhein, an Antidiabetic Nephropathy Drug, Using a Physiologically Based Pharmacokinetic Model
Hao, K., Qu, Q., Wan, P., Zhang, J., Hao, H., Liang, Y. L., Xie, L. Y., Wang, G., & Sun, J. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12148 · Cited by 31
The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development
Heikkinen, A. T., Lignet, F., Cutler, P., & Parrott, N. J. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400147 · Cited by 32
Self-citation
Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis
Li, X., Yang, Y., Zhang, Y. X., Wu, C., Jiang, Q., Wang, W., Li, H., Li, J., Luo, C., Wu, W., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00350 · Cited by 29
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologically Based Models? A Feasibility Study Based on 12 Development Compounds
Parrott, N. J., Manevski, N., & Olivares‐Morales, A. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00350 · Cited by 29
Self-citation
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery
Wuelfing, W. P., Marrouni, A. E., Lipert, M. P., Daublain, P., Kesisoglou, F., Converso, A., & Templeton, A. C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01687 · Cited by 29
Recent Progress on Physiologically Based Pharmacokinetic (PBPK) Model: A Review Based on Bibliometrics
He, H., Zhao, W., Qin, N., & Duan, X. (2024) · Toxics · doi:10.3390/toxics12060433 · Cited by 28
Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Drug Development and in Dietary Phytochemicals
Chou, P. J., Shannar, A., Pan, Y., Dave, P. D., Xu, J., & Kong, A. T. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00427-w · Cited by 35
Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
Gerner, B., & Scherf‐Clavel, O. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060778 · Cited by 28
Drug–drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes
Chenel, M., Bouzom, F., Aarons, L. J., & Ogungbenro, K. (2008) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-008-9104-6 · Cited by 28
Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics
Zhang, M., You, X., Ke, M., Jiao, Z., Wu, H., Huang, P., & Lin, C. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.03.028 · Cited by 28
Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution
von Kleist, M., & Huisinga, W. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9071-3 · Cited by 29
Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling
Zhou, J., You, X., Ke, M., Ye, L., Wu, W., Huang, P., & Lin, C. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.02.001 · Cited by 27
Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection
Tran, T.-D., Pryde, D. C., Jones, P., Adam, F. M., Benson, N., Bish, G., Calo, F., Ciaramella, G., Dixon, R., Duckworth, J. D., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.092 · Cited by 27
Self-citation
Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling
Mansoor, N., Ahmad, T., Khan, R. A., Sharib, S., & Mahmood, I. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000506 · Cited by 27
In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug
Shi, C., Ignjatović, J., Liu, T., Han, M., Cun, D., Djuriš, J., Yang, M., & Cvijić, S. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2020.12.001 · Cited by 26
Prediction of the pharmacokinetics and tissue distribution of levofloxacin in humans based on an extrapolated PBPK model
Zhu, L., Zhang, Y., Yang, J.-W., Wang, Y., Zhang, J., Zhao, Y., & Dong, W. (2015) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-015-0271-8 · Cited by 26
Extrapolating In vitro Metabolic Interactions to Isolated Perfused Liver: Predictions of Metabolic Interactions between R-Bufuralol, Bunitrolol, and Debrisoquine
Haddad, S., Poulin, P., & Funk, C. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22136 · Cited by 26
Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes
Marzolini, C., Rajoli, R. K. R., Battegay, M., Elzi, L., Back, D. J., & Siccardi, M. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0447-7 · Cited by 26
Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals
Shimizu, H., Yoshida, K., Nakada, T., Kojima, K., Ogasawara, A., Nakamaru, Y., & Yamazaki, H. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083642 · Cited by 26
Assessment of drug–drug interactions between voriconazole and glucocorticoids
Li, M., Zhu, L., Chen, L., Li, N., & Qi, F. (2018) · Journal of Chemotherapy · doi:10.1080/1120009x.2018.1506693 · Cited by 28
Commentary on ACCP Position Statement on the Use of Microdosing in the Drug Development Process
Rowland, M. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007310548 · Cited by 26
Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics
Vizirianakis, I. S., Miliotou, Α. N., Mystridis, G. A., Andriotis, E. G., Andreadis, I. I., Papadopoulou, L. C., & Fatouros, D. G. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1605828 · Cited by 25
The Role of Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling in Drug Discovery and Development
Yu, X., & Wilson, A. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.181 · Cited by 25
A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment
Ye, L., Ke, M., You, X., Huang, P., & Lin, C. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.06.010 · Cited by 24
Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model
Gao, Z., Zhu, Y., Yu, M., Zan, B., Liu, J., Zhang, Y., Chen, X., Li, X., & Zhong, D. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.118 · Cited by 24
A physiologically-based flow network model for hepatic drug elimination III: 2D/3D DLA lobule models
Rezania, V., Coombe, D., & Tuszynski, J. A. (2016) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-016-0034-5 · Cited by 24
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data
Sui, X., Sun, J., Li, H., Wang, Y., Liu, J., Liu, X., Zhang, W., Chen, L., & He, Z. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.06.004 · Cited by 24
PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates
Reddy, M. B., Bolger, M. B., Fraczkiewicz, G., Frari, L. D., Luo, L., Lukáčová, V., Mitra, A., Macwan, J. S., Mullin, J. M., Parrott, N. J., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091325 · Cited by 23
Self-citation
Physiologically-based pharmacokinetic modelling and dosing evaluation of gentamicin in neonates using PhysPK
Gómez, H. Z., Lagarejos, E., Prado-Velasco, M., Sánchez-Herrero, S., Serna, J., Rueda-Ferreiro, A., Martín‐Suárez, A., Calvo, M. V. M., Pérez‐Blanco, J. S., & Lanao, J. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.977372 · Cited by 23
Are Physiologically Based Pharmacokinetic Models Reporting the Right Cmax? Central Venous Versus Peripheral Sampling Site
Musther, H., Gill, K. L., Chetty, M., Rostami‐Hodjegan, A., Rowland, M., & Jamei, M. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9796-7 · Cited by 23
Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions
Xia, B., Heimbach, T., Lin, T.-H., He, H., Wang, Y., & Tan, E. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1863-5 · Cited by 23
A Physiologically Based Pharmacokinetic Model for Capreomycin
Reisfeld, B., Metzler, C. P., Lyons, M. A., Mayeno, A. N., Brooks, E. J., & DeGroote, M. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05180-11 · Cited by 23
Evaluation and Optimisation of Current Milrinone Prescribing for the Treatment and Prevention of Low Cardiac Output Syndrome in Paediatric Patients After Open Heart Surgery Using a Physiology-Based Pharmacokinetic Drug–Disease Model
Vogt, W. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0096-z · Cited by 24
An update on computational oral absorption simulation
Dressman, J., Thelen, K., & Willmann, S. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.617743 · Cited by 23
Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients
Thiel, C., Cordes, H., Conde, I., Castell, J. V., Blank, L. M., & Kuepfer, L. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1723-x · Cited by 23
Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling
Huang, W., & Isoherranen, N. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.262154 · Cited by 23
Modeling Pharmacokinetics
Bois, F. Y., & Brochot, C. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3609-0_3 · Cited by 23
Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling
Gibson, C. R., Bergman, A. J., Lü, P., Kesisoglou, F., Denney, W. S., & Mulrooney, E. F. (2009) · Xenobiotica · doi:10.1080/00498250902954296 · Cited by 23
Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives
Zhang, W., Zhang, Q., Cao, Z., Zheng, L., & Hu, W. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122765 · Cited by 22
Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds
Fura, A., Vyas, V. P., Humphreys, W. G., Chimalokonda, A., & Rodrigues, D. (2008) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.632 · Cited by 22
Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico–in vivo extrapolation and physiologically-based pharmacokinetic modeling approach
Malmborg, J., & Ploeger, B. A. (2012) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2012.12.002 · Cited by 22
Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach
Lignet, F., Sherbetjian, E., Kratochwil, N. A., Jones, R., Suenderhauf, C., Otteneder, M. B., Singer, T., & Parrott, N. J. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1982-5 · Cited by 22
Self-citation
Preclinical and Clinical Pharmacokinetics of PF-02413873, a Nonsteroidal Progesterone Receptor Antagonist
Bungay, P. J., Tweedy, S., Howe, D. C., Gibson, K. R., Jones, H. M., & Mount, N. M. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037234 · Cited by 22
Self-citation
Rationalizing Underprediction of Drug Clearance from Enzyme and Transporter Kinetic Data: From In Vitro Tools to Mechanistic Modeling
Galetin, A. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-758-7_13 · Cited by 21
Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds
Mao, J., Ma, F., Yu, J., Bruyn, T. D., Ning, M., Bowman, C. M., & Chen, Y. (2023) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2359 · Cited by 21
PBPK modeling of irbesartan: incorporation of hepatic uptake
Chapy, H., Klieber, S., Brun, P., Gerbal‐Chaloin, S., Boulenc, X., & Nicolas, O. (2015) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1961 · Cited by 20
Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug–drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling
Chen, J., Liu, D., Zheng, X., Zhao, Q., Jiang, J., & Hu, P. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1034688 · Cited by 21
Measurement of Binding of Basic Drugs to Acidic Phospholipids Using Surface Plasmon Resonance and Incorporation of the Data into Mechanistic Tissue Composition Equations to Predict Steady-State Volume of Distribution
Small, H. F., Gardner, I. B., Jones, H. M., Davis, J. D., & Rowland, M. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040253 · Cited by 21
Self-citation
Exploratory Investigation of the Limiting Steps of Oral Absorption of Fluconazole and Ketoconazole in Children Using an In Silico Pediatric Absorption Model.
Cristofoletti, R., Charoo, N. A., & Dressman, J. (2016) · Journal of Pharmacy and Science · doi:10.1016/j.xphs.2016.01.027 · Cited by 21
A sensitive in vitro performance assay reveals the in vivo drug release mechanisms of long-acting medroxyprogesterone acetate microparticles
Gao, G. F., Thurn, M., Wendt, B., Parnham, M. J., & Wacker, M. G. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119540 · Cited by 21
A workflow to build PBTK models for novel species
Schneckener, S., Preuß, T. G., Kuepfer, L., & Witt, J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02922-z · Cited by 21
How to identify and eliminate compounds with a risk of high clinical dose during the early phase of lead optimisation in drug discovery
Teague, S. J., & Valko, K. L. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.02.017 · Cited by 21
In Vitro to in Vivo Extrapolation and Physiologically Based Modeling of Cytochrome P450 Mediated Metabolism in Beagle Dog Gut Wall and Liver
Heikkinen, A. T., Fowler, S., Gray, L., Li, J., Peng, Y., Yadava, P., Railkar, A., & Parrott, N. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300692k · Cited by 20
Self-citation
Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations
van Wijk, R. C., Alsoud, R. A., Lennernäs, H., & Simonsson, U. S. H. (2020) · Applied Sciences · doi:10.3390/app10072376 · Cited by 23
Real-world application of physiologically based pharmacokinetic models in drug discovery
Santos, L. G. A.-A., Jaiswal, S., Chen, K., Jones, H. M., & Templeton, I. E. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.001036 · Cited by 22
Self-citation
Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible
Reddy, M. B., Connor, A. L., Brennan, B. J., Morcos, P. N., Zhou, A., McLawhon, P., Fretland, A. J., Evans, P., Smith, P. F., & Tran, J. Q. (2011) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.756 · Cited by 20
Application of Hybrid Approach Based on Empirical and Physiological Concept for Predicting Pharmacokinetics in Humans—Usefulness of Exponent on Prospective Evaluation of Predictability
Sayama, H., Komura, H., & Kogayu, M. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048819 · Cited by 20
A modified multiparametric assay using HepaRG cells for predicting the degree of drug‐induced liver injury risk
貴文, 富., Okamura, H., Yokoi, T., & Konno, Y. (2016) · Journal of Applied Toxicology · doi:10.1002/jat.3371 · Cited by 19
In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling
Li, X., Liang, E., Hong, X., Han, X., Li, C., Wang, Y., Wang, Z., & Zheng, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010020 · Cited by 19
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART
Roberts, O. L., Rajoli, R. K. R., Back, D. J., Owen, A., Darin, K. M., Fletcher, C. V., Lamorde, M., Scarsi, K. K., & Siccardi, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx515 · Cited by 18
The Pharmacokinetic Prediction of Cyclosporin A after Coadministration with Wuzhi Capsule
Fan, J., Chen, L., Lu, X., Li, M., & Zhu, L. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1444-6 · Cited by 18
Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin
Yang, J. F., Gong, X., Bakh, N. A., Carr, K. M., Phillips, N. F. B., Ismail‐Beigi, F., Weiss, M. A., & Strano, M. S. (2020) · Diabetes · doi:10.2337/db19-0879 · Cited by 19
The discovery of a novel prototype small molecule TLR7 agonist for the treatment of hepatitis C virus infection
Pryde, D. C., Tran, T.-D., Jones, P., Parsons, G. C., Bish, G., Adam, F. M., Smith, M. C., Middleton, D. S., Smith, N. N., Calo, F., et al. (2010) · MedChemComm · doi:10.1039/c0md00197j · Cited by 18
Self-citation
A hybrid framework of artificial intelligence-based neural network model (ANN) and central composite design (CCD) in quality by design formulation development of orodispersible moxifloxacin tablets: Physicochemical evaluation, compaction analysis, and its in-silico PBPK modeling
Khan, M. Z., Yousuf, R. I., Shoaib, M. H., Ahmed, F. R., Saleem, M. T., Siddiqui, F., & Rizvi, S. A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104323 · Cited by 17
Quantitative structure–pharmacokinetic relationships
Xu, C., & Mager, D. E. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.537257 · Cited by 17
Physiologically-based Simulation Modelling for the Reduction of Animal Use in the Discovery of Novel Pharmaceuticals
Thomas, S. (2009) · Alternatives to Laboratory Animals · doi:10.1177/026119290903700507 · Cited by 18
Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin
Parrott, N. J., Hainzl, D., Alberati, D., Hofmann, C., Robson, R. A., Boutouyrie, B. X., & Martin‐Facklam, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0061-x · Cited by 17
Self-citation
Development of a Hybrid Physiologically Based Pharmacokinetic Model with Drug‐Specific Scaling Factors in Rat to Improve Prediction of Human Pharmacokinetics
Sayama, H., Komura, H., Kogayu, M., & Iwaki, M. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23726 · Cited by 16

Authors: Jones, H. M., Parrott, N., Jorga, K., & Lav??, T.
Affiliations: F. Hoffmann-La Roche AG (CH)
Corresponding author: Jones, Hannah M
ORCID: Jones, Hannah M
Parrott, Neil
Venue: Clinical Pharmacokinetics
Publisher: Springer Science and Business Media LLC
Published: 2006
Volume: 45
Issue: 5
Pages: 511-542
ISSN: 0312-5963 (ISSN-L)
DOI: 10.2165/00003088-200645050-00006
OpenAlex: W2146393360
Cited by: 352
References: 76
Citations by year: 2026: 10 · 2025: 13 · 2024: 10 · 2023: 13 · 2022: 18 · 2021: 17 · 2020: 16 · 2019: 17 · 2018: 13 · 2017: 14 · 2016: 20 · 2015: 19 · 2014: 19 · 2013: 19 · 2012: 26
FWCI: 20.15
Type: journal article
Language: en
Open access: closed
Locations: Clinical Pharmacokinetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Keywords: physiologically based pharmacokinetic modelling, human pharmacokinetic prediction, allometry, plasma concentration-time curve, oral clearance, volume of distribution, elimination half-life, prediction accuracy, pharmaceutical compounds
MeSH terms: Animals, Pharmaceutical Preparations, Humans, Models, Biological, Pharmacokinetics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks